Literature DB >> 8709723

Graft-versus-myeloma effect.

J Aschan, B Lönnqvist, O Ringdén, G Kumlien, G Gahrton.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8709723     DOI： 10.1016/s0140-6736(05)64525-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

Review 1.  A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma?

Authors:  Damian J Green; William I Bensinger
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

2.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.

Authors:  S Iacobelli; L C de Wreede; S Schönland; B Björkstrand; U Hegenbart; A Gruber; H Greinix; L Volin; F Narni; A M Carella; M Beksac; A Bosi; G Milone; P Corradini; K Friberg; A van Biezen; H Goldschmidt; T de Witte; C Morris; D Niederwieser; L Garderet; N Kröger; G Gahrton
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

4.  Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  Claire Fabre; Serge Koscielny; Mohamad Mohty; Nathalie Fegueux; Didier Blaise; Natacha Maillard; Reza Tabrizi; Mauricette Michallet; Gérard Socié; Ibrahim Yakoub-Agha; Frédéric Garban; Madalina Uzunov; Sylvie François; Nathalie Contentin; Simona Lapusan; Jean-Henri Bourhis
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

5.  Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

Authors:  Damian J Green; David G Maloney; Barry E Storer; Brenda M Sandmaier; Leona A Holmberg; Pamela S Becker; Min Fang; Paul J Martin; George E Georges; Michelle E Bouvier; Rainer Storb; Marco Mielcarek
Journal:  Blood Adv       Date:  2017-11-09

Review 6.  Bone marrow transplantation using unrelated donors for haematological malignancies.

Authors:  O Ringdén
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

7.  Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.

Authors:  I Ahmad; R LeBlanc; S Cohen; S Lachance; T Kiss; G Sauvageau; D C Roy; L Busque; J-S Delisle; N Bambace; L Bernard; W Sabry; J Roy
Journal:  Bone Marrow Transplant       Date:  2015-12-21       Impact factor: 5.483

Review 8.  Recent developments in hematopoietic stem cell transplantation for multiple myeloma.

Authors:  William I Bensinger
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

Review 9.  Role of autologous and allogeneic stem cell transplantation in myeloma.

Authors:  W I Bensinger
Journal:  Leukemia       Date:  2009-01-29       Impact factor: 11.528

Review 10.  Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?

Authors:  William I Bensinger
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.